108 Days
Source:
الصحة والعلوم الشرق الأوسط
Source: الصحة والعلوم الشرق الأوسط
108 Daysالصحة والعلوم الشرق الأوسط
Source: الصحة والعلوم الشرق الأوسط
108 DaysReady to play
Ready to play
A study funded by Eli Lilly revealed that patients with type 2 diabetes who tried the drug Terzipatide, commercially known as Monarcho, experienced significant improvements in blood sugar control and weight over a two-year period, compared to those using other medications from the GLP-1 class. The results showed that approximately 60% of patients who received Monarcho had normal blood sugar levels, compared to 24% in the control group. The study indicates that early use of this medication may offer greater and more sustainable benefits in managing the disease.
Notice: This Is an AI-Generated Summary
Comments (0)